Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor

Seung Ah Cha1, Byung Mun Park1, Suhn Hee Kim1

  • 1Department of Physiology, Research Institute for Endocrine Sciences, Chonbuk National University Medical School, Jeonju 54907, Korea.

Insights

Angiotensin-(1-9) [Ang-(1-9)] administration reduced pulmonary hypertension in rats by mitigating vascular remodeling, apoptosis, and inflammation via the Angiotensin type 2 receptor (AT2R). This peptide shows promise for treating pulmonary hypertension.

Area of Science:

  • Cardiovascular Research
  • Pulmonary Medicine
  • Renal Physiology

Background:

  • Angiotensin-(1-9) [Ang-(1-9)] is known for protective effects on cardiac and vascular remodeling.
  • The impact of Ang-(1-9) on pulmonary hypertension has not been previously reported.

Purpose of the Study:

  • To investigate the potential of Ang-(1-9) in improving pulmonary vascular remodeling in a rat model of monocrotaline (MCT)-induced pulmonary hypertension.

Main Methods:

  • Sprague-Dawley rats were treated with Ang-(1-9) or saline via osmotic mini-pumps for 3 weeks.
  • Pulmonary hypertension was induced by subcutaneous injection of MCT.
  • Hemodynamic parameters, vascular remodeling, fibrosis, and molecular markers of apoptosis and inflammation were assessed.

Main Results:

  • Ang-(1-9) administration significantly reduced right ventricular hypertrophy and systolic pressure in MCT-induced pulmonary hypertensive rats.
  • Ang-(1-9) attenuated pulmonary arteriolar endothelial damage, medial hypertrophy, and fibrosis.
  • Protective effects were mediated via the Angiotensin type 2 receptor (AT2R) and involved reduced levels of inflammatory cytokines and apoptosis-related proteins.

Conclusions:

  • Angiotensin-(1-9) demonstrates significant therapeutic potential for mitigating MCT-induced pulmonary hypertension.
  • The mechanism involves the downregulation of apoptosis and inflammatory responses through the AT2R pathway.
  • Ang-(1-9) represents a promising novel therapeutic agent for pulmonary hypertension.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
477
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
512
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.1K